Effects of treatment with mometasone furoate dry powder inhaler in children with persistent asthma (Q46652110)

24 December 2017

title

Effects of treatment with mometasone furoate dry powder inhaler in children with persistent asthma (English)

1 reference

24 December 2017

1 reference

William E Berger

1

1 reference

24 December 2017

Henry Milgrom

2

1 reference

24 December 2017

Paul Chervinsky

3

1 reference

24 December 2017

Michael Noonan

4

1 reference

24 December 2017

Steven F Weinstein

5

1 reference

24 December 2017

Barry N Lutsky

6

1 reference

24 December 2017

Heribert Staudinger

7

1 reference

24 December 2017

publication date

1 November 2006

1 reference

24 December 2017

Annals of Allergy, Asthma & Immunology

published in

1 reference

24 December 2017

volume

97

1 reference

24 December 2017

issue

5

1 reference

24 December 2017

page(s)

672-680

1 reference

24 December 2017

Long-term effects of budesonide or nedocromil in children with asthma.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961099-X

7 January 2021

The Prevention of Early Asthma in Kids study: design, rationale and methods for the Childhood Asthma Research and Education network

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961099-X

7 January 2021

Early introduction of inhaled steroids in wheezing children presenting in primary care. A pilot study. EASE Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961099-X

7 January 2021

Effects of budesonide inhalation suspension compared with cromolyn sodium nebulizer solution on health status and caregiver quality of life in childhood asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961099-X

7 January 2021

The effect of fluticasone propionate on functional status and sleep in children with asthma and on the quality of life of their parents.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961099-X

7 January 2021

Mometasone furoate. A review of its intranasal use in allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961099-X

7 January 2021

Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961099-X

7 January 2021

Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961099-X

7 January 2021

Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961099-X

7 January 2021

Once-daily evening administration of mometasone furoate in asthma treatment initiation

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961099-X

7 January 2021

Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961099-X

7 January 2021

Standardization of Spirometry, 1994 Update. American Thoracic Society

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961099-X

7 January 2021

Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961099-X

7 January 2021

Drug delivery performance of the mometasone furoate dry powder inhaler

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961099-X

7 January 2021

10.1016/S1081-1206(10)61099-X

Identifiers

DOI

1 reference

24 December 2017

PubMed ID

17165278

1 reference

24 December 2017